Essential Thrombocythemia
📧 Sign up to get email alerts when something new happens for Essential Thrombocythemia.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2018-03-20FDA Approved: AGRYLIN — Supplemental Application (Takeda Pharmaceuticals America, Inc.)
FDA approved a supplemental NDA for AGRYLIN (anagrelide hydrochloride) by Takeda Pharmaceuticals America, Inc., representing an approved sup…
-
CLINICAL_TRIALS trial_result · 2018-01-24Clinical Trial Update: A Study of Anagrelide and Hydroxyurea in High-Risk Essential Thrombocythemia Patients [Phase 4]
Phase 4 trial update for anagrelide and hydroxyurea in high-risk essential thrombocythemia completed with results posted.
-
FDA approval · 2017-12-18FDA Approved: DROXIA — Supplemental Application (Waylis Therapeutics LLC)
FDA approved a supplemental application for DROXIA (hydroxyurea) submitted by Waylis Therapeutics LLC.
-
CLINICAL_TRIALS research · 2017-07-26Clinical Trial Update: Hydroxyurea Versus Aspirin and Hydroxyurea in Essential Thrombocythemia [Phase 3]
This clinical trial update describes a Phase 3 study comparing hydroxyurea alone versus hydroxyurea with aspirin in essential thrombocythemi…
-
CLINICAL_TRIALS research · 2017-07-02Clinical Trial Update: Molecular Changes and Biomarkers in Chronic Myeloproliferative Disorders
A completed NIH-backed clinical trial examining molecular changes and biomarkers in chronic myeloproliferative disorders including polycythe…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2017-06-30FDA Approved: ANAGRELIDE — Original Application (Torrent Pharmaceuticals Limited)
The FDA approved a generic version of anagrelide under an Original Application submitted by Torrent Pharmaceuticals Limited for the treatmen…
-
CLINICAL_TRIALS trial_result · 2017-04-24Clinical Trial Update: Study to Assess the Safety of AZD1480 in Patients With Myeloproliferative Diseases [Phase 1]
A Phase 1 trial evaluating the safety of AZD1480 in adults with myeloproliferative diseases has completed, with results posted in 2017.
-
CLINICAL_TRIALS trial_result · 2017-04-12Clinical Trial Update: Study of LY2784544 Testing Alternative Dosing in Participants With Myeloproliferative Neoplasms [Phase 1]
Phase 1 study of LY2784544 testing alternative dosing in patients with myeloproliferative neoplasms, including polycythemia vera, essential …
-
CLINICAL_TRIALS trial_result · 2017-03-29Clinical Trial Update: Biological Therapy in Treating Patients With Advanced Myelodysplastic Syndrome, Acute or Chronic Myeloid Leukemia, or Acute Lymphoblastic Leukemia Who Are Undergoing Stem Cell Transplantation [Phase 1, Phase 2]
A Phase 1/2 clinical trial update reports completion of a study evaluating an investigational biological therapy in adults with advanced mye…
-
CLINICAL_TRIALS trial_result · 2017-01-18Clinical Trial Update: Primary Thrombocythaemia 1 Trial [NA]
This is a completed status update for the Primary Thrombocythemia 1 clinical trial conducted by the University of Cambridge.
-
CLINICAL_TRIALS trial_result · 2017-01-11Clinical Trial Update: Pegylated Interferon Alfa-2a Salvage Therapy in High Risk Polycythemia Vera (PV) or Essential Thrombocythemia (ET) [Phase 2]
A Phase 2 trial evaluating pegylated interferon alfa-2a as salvage therapy in high-risk polycythemia vera or high-risk essential thrombocyth…
-
CLINICAL_TRIALS withdrawal · 2016-10-24Clinical Trial Update: Siltuximab in Treating Patients With Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis [EARLY_Phase 1]
Northwestern University’s early-phase trial of siltuximab for myelofibrosis, including primary, post-polycythemia vera, and post-essential t…
-
CLINICAL_TRIALS trial_result · 2016-06-15Clinical Trial Update: Retrospective Data Collection of Routine Use With Spectra Optia® for Platelet Depletions
A retrospective data collection evaluating routine use of the Spectra Optia device for platelet depletions.
-
CLINICAL_TRIALS trial_result · 2016-06-08Clinical Trial Update: Long-term Safety of SPD422 in Japanese Adults With Essential Thrombocythaemia [Phase 3]
Phase 3 trial update reporting long-term safety of SPD422 in Japanese adults with essential thrombocythemia.
-
CLINICAL_TRIALS trial_result · 2016-05-26Clinical Trial Update: Anagrelide Retard vs. Placebo: Efficacy and Safety in "At-risk" Patients With Essential Thrombocythaemia [Phase 3]
A Phase 3 trial comparing anagrelide retard to placebo in at-risk patients with essential thrombocythemia reports efficacy and safety result…
-
CLINICAL_TRIALS trial_result · 2016-05-23Clinical Trial Update: HSP90 Inhibitor, AUY922, in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), and Refractory PV/ET [Phase 2]
Phase 2 trial of the HSP90 inhibitor AUY922 in myeloproliferative neoplasms including primary myelofibrosis and MF after PV/ET was terminate…
-
CLINICAL_TRIALS withdrawal · 2016-04-20Clinical Trial Update: Cell Cycle Regulatory Gene Study in Patients With Myeloproliferative Disorders
A clinical trial (NCT02663648) evaluating a cell cycle regulatory gene study in myeloproliferative neoplasms has been withdrawn by the spons…
-
FDA approval · 2016-03-23FDA Approved: DROXIA — Supplemental Application (Waylis Therapeutics LLC)
FDA approved a supplemental application for DROXIA (hydroxyurea) filed by Waylis Therapeutics LLC.
-
CLINICAL_TRIALS trial_result · 2016-01-26Clinical Trial Update: Open Label Study to Evaluate the Activity of Imetelstat in Patients With Essential Thrombocythemia or Polycythemia Vera [Phase 2]
An open-label Phase 2 trial evaluating imetelstat in essential thrombocythemia or polycythemia vera has completed.
-
CLINICAL_TRIALS research · 2015-11-17Clinical Trial Update: Safety and Pregnancy Outcomes in Thrombocythemia Patients Exposed to XAGRID® (Anagrelide Hydrochloride) Compared to Other Treatments
Clinical trial update reporting safety and pregnancy outcomes in thrombocythemia patients exposed to XAGRID compared with other treatments.
-
CLINICAL_TRIALS trial_result · 2015-07-29Clinical Trial Update: Anagrelide Retard in Essential Thrombocythemia [Phase 3]
Phase 3 trial update for Anagrelide Retard in essential thrombocythemia; the study status is completed.
-
FDA label_change · 2015-07-14FDA Approved: AGRYLIN — Supplemental Application (Takeda Pharmaceuticals America, Inc.)
FDA approved a supplemental application for AGRYLIN (anagrelide hydrochloride) submitted by Takeda Pharmaceuticals America, Inc. to update t…
-
FDA approval · 2015-06-01FDA Approved: ANAGRELIDE — Supplemental Application (Chartwell RX, LLC)
The FDA approved a supplemental application for ANAGRELIDE from Chartwell RX, LLC, supporting the approval of this generic product. The acti…
-
CLINICAL_TRIALS research · 2014-11-26Clinical Trial Update: CEP-701 (Lestaurtinib) in Myelofibrosis [Phase 1, Phase 2]
Clinical trial update on CEP-701 (lestaurtinib) in myelofibrosis, with additional conditions essential thrombocythemia and polycythemia vera…
-
FDA approval · 2014-10-30FDA Approved: AGRYLIN — Supplemental Application (Takeda Pharmaceuticals America, Inc.)
The FDA approved a supplemental application for AGRYLIN (anagrelide hydrochloride) submitted by Takeda Pharmaceuticals America, Inc. This ap…